Neulastim

Pegfilgrastim

Reduction in duration of neutropenia, incidence of febrile neutropenia & infection as manifested by febrile neutropenia in patients treated w/ cytotoxic chemotherapy for malignancy (w/ the exception of chronic myeloid leukemia & myelodysplastic syndromes).

SC Administer into the thigh, abdomen or upper arm. Adult ≥18 yr 1 dose for each chemotherapy cycle, given at least 24 hr after cytotoxic chemotherapy.

Hypersensitivity.

Do not administer in patients w/ history of hypersensitivity to pegfilgrastim or filgrastim. Permanently discontinue in patients w/ hypersensitivity. Discontinue therapy if preliminary signs of acute resp distress syndrome occur. Sickle cell trait or sickle cell disease; leukocytosis. Immunogenicity. Aortitis; SJS. Mobilisation of blood progenitor cells. Increased hematopoietic bone marrow activity associated w/ transient +ve bone-imaging findings. Patients w/ de novo AML (<55 yr w/ cytogenetics); secondary AML, myelodysplastic syndrome & chronic myelogenous leukemia; receiving high-dose chemotherapy. Recent history of pulmonary infiltrates or pneumonia. Urinalysis monitoring for glomerulonephritis. Closely monitor patients who develop capillary leak syndrome; treated in setting for signs & symptoms of MDS/AML. Carefully monitor spleen size for splenomegaly & spleen rupture. Regularly monitor platelet count & hematocrit. Perform WBC count at regular intervals during therapy. Products containing sorbitol (or fructose) & dietary intake of sorbitol (or fructose). Pregnancy & lactation.

Headache; nausea; bone pain. Thrombocytopenia, leukocytosis; musculoskeletal pain (myalgia, arthralgia, pain in extremity, back & neck pain); inj site pain, non-cardiac chest pain.

Potentiate myelosuppression w/ 5-fluorouracil or other antimetabolites.

Supportive Care Therapy / Haematopoietic Agents

L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.

S